But the needs of patients and families living with genetic diseases are immediate and vast,” said Jeffrey D. “As the only biotechnology company that has successfully commercialized a gene therapy for a genetic disease in the U.S., we have built unmatched competencies in the discovery, development and delivery of genetic medicines. Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all outstanding shares of Spark’s common stock, and Spark will file a recommendation statement containing the unanimous recommendation of the Spark board that Spark shareholders tender their shares to Roche. The merger agreement has been unanimously approved by the boards of both Spark and Roche. The per share price represents a premium of 122 percent to Spark’s closing price on Feb. This corresponds to a total equity value of approximately $4.8 billion on a fully diluted basis, inclusive of approximately $500 million of projected net cash expected at close. 25, 2019 (GLOBE NEWSWIRE) - Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction. Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion Spark Therapeutics will continue its operations in Philadelphia as an independent company within the Roche Group Transaction expected to close in Q2, 2019
0 kommentar(er)
